# US 2014/0370039 A1 · Il-12 immunotherapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0370039 A1
- Document ID: US20140370039A1
- Status: Published application
- Kind: A1
- Application number: 14/283,966
- Filed: 2014-05-21
- Published: 2014-12-18
- Earliest claimed: 2007-05-04
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: Jeffrey A. Medin; Christopher J. Paige
- Web page: https://patentgrep.com/patent/US20140370039A1

## CPC

- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/208: {IL-12}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/4234: {Interleukins [IL]}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C07K 14/5434: {IL-12}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/515: {Animal cells}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/00: Fusion polypeptide
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15071: Demonstrated in vivo effect
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2800/40: Systems of functionally co-operating vectors
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/60: from viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

## Claims

### Claim at position 1

-23. (canceled)

### Claim 24

A method of expressing IL-12 in a cell that is secreted above a threshold level, optionally a cancer cell, comprising: contacting the cell with a composition comprising a vector construct or an isolated virus comprising a lentiviral delivery vector and an IL-12 expression cassette, wherein the lentiviral delivery vector comprises a central polypurine tract (cPPT) sequence, optionally SEQ ID NO: 2 and/or a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), optionally SEQ ID NO: 3, under conditions that permit transduction of the cell, thereby providing a transduced cell, wherein the IL-12 is secreted and the IL-12 secreted per cell is above a threshold level.

### Claim 25 (depends on 24)

The method of claim 24, further comprising a step of isolating the transduced cell or isolating a population of cells comprising the transduced cell.

### Claim 26 (depends on 24)

The method of claim 24, further comprising:
a. growth arresting the transduced cell or the population of cells; and
b. optionally introducing the transduced growth arrested cell, population of cells and/or a composition comprising said transduced growth arrested cell or population of cells in a subject.

### Claim at position 5

-29. (canceled)

### Claim 30 (depends on 31)

The method of claim 31, wherein the cancer is leukemia, optionally ALL, AML, CML or CLL.

### Claim 31

A method of inducing or enhancing an immune response, optionally a memory immune response in a subject, optionally with cancer or an increased risk of cancer and/or treating a subject with cancer or an increased risk of cancer comprising administering: i) an isolated virus-comprising a lentiviral delivery vector and an IL-12 expression cassette wherein the lentiviral vector comprises a central polypurine tract (cPPT) sequence, optionally SEQ ID NO: 2 and/or a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), optionally SEQ ID NO: 3, ii) a transduced cell comprising a lentiviral delivery vector and an IL-12 expression cassette wherein the transduced cell expresses IL-12 above a threshold level iii) a population of cells comprising the transduced cell of ii), or iv) a composition comprising i), ii) and/or iii).

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The method of claim 31 wherein the transduced cell is growth arrested prior to administering to the subject, optionally wherein the transduced cell is irradiated prior to administering to the subject.

### Claim 35

(canceled)

### Claim 36

A method of delivering IL-12 to a subject, optionally with cancer or an increased risk or cancer, optionally, for enhancing cancer treatment comprising:
a. generating a recombinant IL-12 secreting cell wherein the IL-12 secreted per cell is above a threshold level; and
b. introducing an effective number of the generated recombinant IL-12 secreting cells to the subject, optionally in a population of cells comprising the recombinant IL-12 secreting cell.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 36)

The method of claim 36 wherein the threshold level of IL-12 secreted is at least 1.5 fg/ml cells/2 hrs of IL-12, at least 1.5 pg/ml cells/2 hrs of IL-12, or at least 1500 pg/mL/106 cells/2 hrs of IL-12, optionally at least 1500 pg/mL/106 cells/2 hrs, 1500-2500 pg/mL/106 cells/2 hrs, 2500-5000 pg/mL/106 cells/2 hrs, 5000-7500 pg/mL/106 cells/2 hrs, 7500-10000 pg/mL/106 cells/2 hrs, 10000-12500 pg/mL/106 cells/2 hrs, 12500-15000 pg/mL/106 cells/2 hrs, 15000-17500 pg/mL/106 cells/2 hrs, 17500-20000 pg/mL/106 cells/2 hrs or at least 20000 pg/mL/106 cells/2 hrs of IL-12.

### Claim 40 (depends on 36)

The method of claim 36, wherein the recombinant IL-12 secreting cell is generated by contacting the cell with a composition comprising a lentiviral delivery vector and an IL-12 expression cassette, wherein the lentiviral delivery vector comprises a central polypurine tract (cPPT) sequence, optionally SEQ ID NO: 2 and/or a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), optionally SEQ ID NO: 3.

### Claim 41 (depends on 36)

The method of claim 36, wherein the recombinant cell is a cancer cell, optionally derived from the subject with cancer.

### Claim 42 (depends on 36)

The method of claim 36, wherein the recombinant cell or population of cells are introduced by IP injection, subcutaneously or intradermally.

### Claim 43 (depends on 36)

The method of claim 36, wherein the cancer is a leukemia, optionally ALL, AML, CML or CLL.

### Claim 44 (depends on 36)

The method of claim 36, wherein the IL-12 secreting cell is growth arrested prior to introducing to the subject.

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 31)

The method of claim 31, wherein the immune response leads to long-term immune memory and/or does not induce or enhance antagonistic cytokines, and/or wherein the response is initiated substantially free of inducing or enhancing of a CD8+ T cell-dependent immune response.

### Claim 48

(canceled)

### Claim 49 (depends on 31)

The method of claim 31 wherein the level of IL-12 secreted is above a threshold level that enhances dendritic cell maturation and/or antigen presentation.

### Claim at position 26

-71. (canceled)

### Claim 72 (depends on 36)

The method of claim 36, wherein the number of cells introduced ranges from 105 cells to 109 cells, optionally about 105, about 106 cells, about 107 cells, about 108 cells, or about 109 cells.

### Claim 73

(canceled)

### Claim 74 (depends on 36)

The method of claim 36 wherein the population of cells optionally comprises at least 0.1 to 1% IL-12 producing leukemic cells, optionally about 0.5%, about 1%, about 1-5%, 5-10%, 10-20% or more IL-12 producing leukemic cells, and wherein the population of cells secretes above the threshold level optionally the threshold level necessary to induce or enhance a CD4+ T cell dependent immune response, optionally at least 1500 pg/mL/106 cells/2 hrs, 1500-2500 pg/mL/106 cells/2 hrs, 2500-5000 pg/mL/106 cells/2 hrs, 5000-7500 pg/mL/106 cells/2 hrs, 7500-10000 pg/mL/106 cells/2 hrs, 10000-12500 pg/mL/106 cells/2 hrs, 12500-15000 pg/mL/106 cells/2 hrs, 15000-17500 pg/mL/106 cells/2 hrs, 17500-20000 pg/mL/106 cells/2 hrs or at least 20000 pg/mL/10 cells/2 hrs of IL-12.

### Claim 75 (depends on 24)

The method of claim 24, wherein the IL-12 expression cassette comprises a polynucleotide optionally encoding a p35 polypeptide and a polynucleotide encoding a p40 polypeptide; or a polynucleotide encoding an IL-12 fusion polypeptide.

### Claim 76 (depends on 75)

The method of claim 75 wherein the IL-12 fusion polypeptide has at least 70% sequence identity to SEQ ID NO: 4 and binds an IL-12 receptor.

### Claim 77 (depends on 24)

The method of claim 24 wherein the vector construct further comprises one or more of: an activator polynucleotide encoding a polypeptide that converts a prodrug to a drug, optionally a modified tmpk polynucleotide; a detection cassette, optionally a CD19, truncated CD19, CD20, human CD24, murine HSA, human CD25 (huCD25), a truncated form of low affinity nerve growth factor receptor (LNGFR), truncated CD34, eGFP, eYFP, or any other fluorescent protein or erythropoietin receptor (EpoR) polynucleotide; or a polynucleotide with at least 70% sequence identity to said polynucleotide; and an immune modulatory cassette, optionally a polynucleotide that encodes a polypeptide that modulates an immune cell, optionally a dendritic cell or a T cell, optionally a CD4+ T cell, optionally CD40L, IL-7, or IL-15.
